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Early lymphocyte recovery is associated with improved
progression free survival (PFS) after autologous stem cell
transplantation in multiple myeloma (MM). In fact, the
number of infused autograft NK cells was found to correlate
directly with early absolute lymphocyte count (ALC) in
retrospective, subset analyses. To assess a potential role for
re-infused lymphocytes in post-transplant outcome, we
characterized stem cell graft lymphocyte subsets in associ-
ation with post-transplant immune reconstitution and sur-
vival in MM. We studied clinical patient outcomes and
performed immunophenotypic analyses on cryopreserved
apheresis samples from 27 MM patients to determine
whether a particular immunophenotypic proﬁle correlated
with early ALC and/or PFS after transplant. We investigated
subsets using markers on NK cells, T cells, and B cells. Out of
the phenotypic analyses performed, the single strong signal
associated with an improved outcome was an inverse cor-
relation between NKG2A expression on cytolytic CD56dim
NK cells and survival (p¼0.011, Spearman’s r¼-0.480). This
suggests that reduced inhibition of NK cells through NKG2A
leads to improved outcomes after ASCT. Interestingly, this
beneﬁcial decrease in NKG2A expression was also correlated
with a trending decrease in pro-inﬂammatory Th1 cells
(p¼0.086, Spearman’s r¼0.336). Although lacking statistical
signiﬁcance in our small sample size, the increased presence
of Th1 pro-inﬂammatory T cells in the stem cell graft
appeared to negatively correlate with PFS (p¼0.109, Spear-
man’s r¼0.136). These data suggest that the presence of a
skewed immune cell phenotype toward amore activating NK
cell proﬁle (decreased inhibition through NKG2A) and away
from a pro-inﬂammatory T cell proﬁle within the stem cell
graft could confer improved PFS. While our data did not
show a correlation between an increased proportion of NK
cells in the graft and survival, they suggest that a less
inhibited NK cell proﬁle could mediate differences in patientFigure 1. Pretransplant MRD predicts outcome of mantle cell lymphoma patients in c
and (b) progression-free survival.outcome after transplant. Further investigation should be
aimed at delineating the role of NKG2A on reconstituting NK
cells following autograft, and the potential efﬁcacy of NKG2A
blockade in immune recovery and tumor surveillance in or-
der to unlock translational avenues to increase survival in the
post-transplant setting.
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Background: High-dose therapy and autologous stem cell
transplantation (ASCT) is a standard therapy for mantle cell
lymphoma (MCL) patients in ﬁrst remission following in-
duction chemotherapy yet outcomes following this approach
are variable even for patients in complete remission (CR). The
presence of minimal residual disease (MRD) has been shown
to be associated with outcome in other settings, yet limited
data exist on the utility of this measure prior to ASCT. We
hypothesized that evaluation of MRD prior to initiation of
conditioning could stratify CR patients into high or low risk
of relapse and could be used to guide additional post-
transplant therapies.
Methods: Sequential patients with conﬁrmed MCL, age  18
years who underwent ASCT between 1996 and 2011 at the
Fred Hutchinson Cancer Research Center, University ofomplete remission undergoing ASCT. Kaplan-Meier plots for (a) overall survival
